辛伐他汀对继发进展型多发性硬化残疾进展的影响(MS-STAT2):一项3期随机双盲安慰剂对照试验
MS-STAT2是一项在英国31个中心开展的3期随机双盲安慰剂对照试验,964例18-65岁继发进展型多发性硬化患者随机接受口服辛伐他汀80 mg或安慰剂治疗最长4.5年。辛伐他汀组192例(40%)与安慰剂组173例(36%)出现6个月确认的残疾进展,校正风险比1.13(95%CI 0.91-1.39,p=0.26),未显示治疗效应。
要点
- 辛伐他汀80 mg未延缓继发进展型多发性硬化的残疾进展,校正风险比1.13(95%CI 0.91-1.39,p=0.26)。
- 辛伐他汀组发生1例严重不良反应(横纹肌溶解),未发现新的安全性问题。
- 作者认为辛伐他汀在多发性硬化中的使用应限于现有的血管适应证。
核心结论
- MS-STAT2试验未显示辛伐他汀在延缓继发进展型多发性硬化残疾进展方面的治疗效应。
- 作者认为辛伐他汀在多发性硬化中的使用应限于现有的血管适应证。
研究设计与样本
- 3期随机双盲平行组安慰剂对照临床试验,在英国31个神经科学中心和地区综合医院开展。
- 纳入18-65岁、诊断为继发进展型多发性硬化且扩展残疾状态量表(EDSS)评分在4.0至6.5之间的患者。
- 按1:1随机分配至口服辛伐他汀80 mg组或匹配安慰剂组,治疗最长4.5年,采用独立安全在线随机化服务中的最小化算法。
- 所有参与者、中心研究者和试验协调团队对治疗分配设盲。
- 主要结局为至6个月确认的EDSS残疾进展时间,在所有随机分配参与者中按意向性治疗分析、不做填补;共筛查1079例,随机分配964例(安慰剂组482例,辛伐他汀组482例)。
主要发现
- 964例参与者中704例(73%)为女性、260例(27%)为男性,平均年龄54岁(SD 7)。
- 安慰剂组482例中173例(36%)与辛伐他汀组482例中192例(40%)出现6个月确认的残疾进展,校正风险比1.13(95%CI 0.91至1.39,p=0.26)。
- 未发现新的安全性问题,辛伐他汀组发生1例严重不良反应(横纹肌溶解)。
- 安慰剂组482例中12例(2%)与辛伐他汀组482例中5例(1%)发生心血管严重不良事件。
临床怎么用
- 作者认为辛伐他汀在多发性硬化中的使用应限于现有的血管适应证。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite the success of immune modulation in the treatment of relapsing multiple sclerosis, disability progression is a major problem driven by multiple mechanisms. Comorbidities (eg, vascular risk) and ageing are thought to augment these neurodegenerative pathologies. In the phase 2b MS-STAT trial of simvastatin (80 mg) versus placebo in secondary progressive multiple sclerosis (SPMS), the adjusted difference in brain atrophy rate between groups was -0·254% per year: a 43% reduction. In this phase 3 MS-STAT2 trial, we aimed to assess the efficacy of simvastatin versus placebo in slowing the progression of disability in SPMS. METHODS: This phase 3, randomised, double-blind, parallel group, placebo-controlled clinical trial was conducted at 31 neuroscience centres and district general hospitals in the UK. Participants aged 18-65 years with a diagnosis of SPMS and an Expanded Disability Status Scale (EDSS) of between 4·0 and 6·5 were eligible and randomly assigned (1:1) to oral simvastatin (80 mg) or matched placebo for up to 4·5 years, based on a minimisation algorithm within an independent and secure online randomisation service. All participants, site investigators, and the trial coordinating team were masked to treatment allocation. The primary outcome was time to 6-month EDSS confirmed disability progression (an increase of at least 1 point if EDSS score at baseline visit was less than 6·0 or an increase of 0·5 point if EDSS score at baseline visit was 6·0 or more) assessed in all randomly assigned participants (intention-to-treat analysis) without imputation. This study is registered with ClinicalTrials.gov (NCT03387670) and is on the ISRCTN registry (ISRCTN82598726). The study is completed. FINDINGS: Between May 10, 2018, and July 26, 2024, 1079 patients were screened for eligibility and 964 participants were randomly assigned, with 482 (50%) in the placebo group and 482 (50%) in the simvastatin group. Of all 964 participants, 704 (73%) were female and 260 (27%) were male, with a mean age of 54 years (SD 7). 173 (36%) of 482 participants in the placebo group and 192 (40%) of 482 participants in the simvastatin group had 6-month confirmed disability progression (adjusted hazard ratio 1·13 [95% CI 0·91 to 1·39], p=0·26). Although no emergent safety issues were seen, there was one serious adverse reaction (rhabdomyolysis) in the simvastatin group. 12 (2%) of 482 participants in the placebo group and five (1%) of 482 participants in the simvastatin group had a cardiovascular serious adverse event. INTERPRETATION: The MS-STAT2 trial did not show a treatment effect of simvastatin in slowing disability progression in SPMS. Simvastatin use in multiple sclerosis should be confined to existing vascular indications. FUNDING: National Institute for Health and Care Research Health Technology Assessment Programme, UK Multiple Sclerosis Society, and the US National Multiple Sclerosis Society.
引用
- Chataway J, Williams T, Blackstone J, et al. Effect of repurposed simvastatin on disability progression in secondary progressive multiple sclerosis (MS-STAT2): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2025. PMID: 41045938. doi:10.1016/S0140-6736(25)01039-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。